- Home
- ATAI vs IMTX Comparison
ATAI vs IMTX Comparison
Compare ATAI & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATAI | IMTX |
|---|---|---|
| Founded | 2018 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATAI | IMTX |
|---|---|---|
| Price | $4.05 | $9.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $15.88 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 5.3M | 487.0K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,089,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1227.60 | N/A |
| 52 Week Low | $2.00 | $5.05 |
| 52 Week High | $6.73 | $12.41 |
Technical Indicators
Market Signals| Indicator | ATAI | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 46.25 |
| Support Level | $3.47 | $9.77 |
| Resistance Level | $4.20 | $10.64 |
| Average True Range (ATR) | 0.31 | 0.55 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 31.20 | 45.26 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.